治疗慢性阻塞性肺疾病的药物研究进展

馥玮 巩(齐鲁医药学院，中国)

摘要

慢性堵塞性肺病（Chronic Obstructive Pulmonary Disease, COPD）是一种发病率及死亡率都很高的慢性疾病。COPD是一种以持续性呼吸道症状和气流受限为特征的可以预防和治疗的疾病，呼吸道症状和气流受限是由有毒颗粒或气体导致的气道和/或肺泡异常引起的。 COPD的发病原因主要是吸入有害颗粒和气体，最常见的就是吸烟、粉尘、化学物及空气污染等因素。以往临床上一般采用单方支气管扩张剂和抗炎药物对COPD进行治疗，随着对该疾病病理机制的深入研究，复方制剂也已逐渐应用于临床。论文针对包括支气管扩张剂及其组成的复方制剂治疗药物在内的COPD治疗药物的研究进展进行综述。

关键词

慢性阻塞性肺疾病；治疗药物；支气管扩张剂；复方制剂

参考

Rennard S I. Treatment of stable chronic obstructive pulmonary disease[J]. Lancet (North American Edition), 2004, 364(9436):0-802.

Sutherland E. Management of chronic obstructive pulmonary disease[J]. Journal of the Indian Medical Association, 1969, 50(3):324-325.

马丹,沈继奋.慢性阻塞性肺部疾病的药物治疗研究进展[J].医药导报,2003,22(6):364-366.

Barnes, P. J . COPD: current therapeutic interventions and future approaches[J]. European Respiratory Journal, 2005, 25(6):1084-1106.

Anthonisen N R , Connett J E , Kiley J P , et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study.[J]. JAMA, 272.

Scanlon P D, Connett J E, Waller L A, et al. Smoking Cessation and Lung Function in Mild-to-Moderate Chronic Obstructive Pulmonary Disease[J]. American Journal of Respiratory & Critical Care Medicine,2000, 161(2 Pt 1):381.

冯玉麟.慢性阻塞性肺疾病发病的分子机制[J].中华结核和呼吸杂志,2005,28(7):438-440.

韩飞,赵志冬,王跃生,etal.肺部吸入制剂评价方法的研究进展[J].中国实验方剂学杂志,2012,18(11):303-306.

Vestbo J, Hurd S S, Rodriguezroisin R. [An overview of Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease (GOLD) (revised 2011)].[J]. Zhonghua Yi Xue Za Zhi, 2012, 92(14):937.

Cosio B G, Iglesias A, Rios A, et al. Low-dose theophylline enhances the anti-inflammatory effects of steroids during exacerbations of COPD[J]. Thorax, 2009, 64(5):424-429.

Martin L, Hutchens M, Hawkins C, et al. How much do clinical trials cost?[J]. NATURE REVIEWS DRUG DISCOVERY, 2017.

秦茵茵.吸入糖皮质激素和长效β_2受体激动剂治疗支气管哮喘[J].国际呼吸杂志,2002,22(5):266-269.

Bone R C. Goals of asthma management. A step-care approach.[J]. Chest, 1996, 109(4):1056-65.

Chapman K R. The role of anticholinergic bronchodilators in adult asthma and chronic obstructive pulmonary disease[J]. Lung, 1990, 168(1):295.

Noord J A V, Aumann J L, Janssens E, et al. Effects of Tiotropium With and Without Formoterol on Airflow Obstruction and Resting Hyperinflation in Patients With COPD[J]. Chest, 2006, 129(3):509-517.

Eguchi Y, Tateishi Y, Umeda N, et al. Effects of tiotropium or combined therapy with salmeterol on hyperinflation in COPD[J]. Osaka city medical journal, 2007, 53(1):25-34.

Syed Y Y, Lyseng-Williamson K A. Fluticasone furoate/umeclidinium/vilanterol dry-powder inhaler in COPD: a profile of its use in the EU[J]. Drugs & Therapy Perspectives, 2018, 34(6):241-247.

Page C, Cazzola M. Bifunctional drugs for the treatment of asthma and chronic obstructive pulmonary disease[J]. European Respiratory Journal, 2014, 44(2):475-482.

向左娟,孙宏斌.慢性阻塞性肺疾病的发病机制和临床药物研究进展[J].药学与临床研究,2013,21(1):47-51.

DOI: http://dx.doi.org/10.26549/yzlcyxzz.v4i3.6890